BUY Dr. Reddy's Laboratories LimitedAmit Seth

byAmit SethHorizon: NA (inferred Swing (≤2wk))21 Sept 2026via CNBC Awaaz.

Entry₹1,197.2Inferred
Target₹1,220
Stop loss₹1,184-1.10% risk
CMP₹1,2116h ago
Active+1.15%+0.74%upside left 13d left

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Sept, 10:32 pm IST
6 supporting1 opposing
Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·22 Sept · today

4 advisors have active short-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·21 Sept · yesterday

Dr. Reddy's Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for Qdenga®, a dengue vaccine, in the private market in India. The agre

BSE · Company Update·18 Sept · 4d ago

(opens in new tab)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·17 Sept · 5d ago

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · 6d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.